Department of cardiology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
J Clin Nurs. 2018 Mar;27(5-6):e951-e958. doi: 10.1111/jocn.14050.
To evaluate the prevalence and predictors of smoking relapse after percutaneous coronary intervention in Chinese patients.
Smoking is considered a vital risk factor for coronary heart disease. Although smoking cessation could decrease the risks of adverse cardiac outcomes, many patients resume smoking following a short period of abstinence. However, little is known about smoking resumption in patients who have undergone percutaneous coronary intervention.
A longitudinal study was conducted among Chinese patients who underwent percutaneous coronary intervention. Predictive variables were assessed at baseline through medical records and interviews with questionnaires including the Fagerström Test for Nicotine Dependence, Center for Epidemiologic Studies-Depression scale and Smoking Self-Efficacy Questionnaire. Smoking relapses were recorded at three, six, nine and 12 months by the self-reporting through telephone or at routine visits to the cardiology outpatient clinics.
A total of 221 patients who quit smoking immediately after percutaneous coronary intervention completed the whole study. Overall, 51.1%(n = 113) of the patients relapsed within 12 months after percutaneous coronary intervention. The prevalence showed a particular rise (49.6%, n = 56) in the first 3 months and a more gradual increase in the following months. The patients who were employed and had higher nicotine dependence, worse depressive symptoms and lower level of smoking self-efficacy were more vulnerable to relapse to cigarettes.
The prevalence of smoking relapse is high in the patients who stop smoking in the hospital due to percutaneous coronary intervention. The predictors of smoking relapse are employment, nicotine dependence, depression and smoking self-efficacy in the post- percutaneous coronary intervention patients.
This study may prompt the healthcare providers to focus on the issue of smoking relapse and provide some instructions for identification of the patients with a high-risk of relapse after percutaneous coronary intervention.
评估中国经皮冠状动脉介入治疗患者吸烟复发的患病率和预测因素。
吸烟被认为是冠心病的一个重要危险因素。虽然戒烟可以降低不良心脏事件的风险，但许多患者在短暂的戒断后会重新吸烟。然而，对于已经接受经皮冠状动脉介入治疗的患者，吸烟复发的情况知之甚少。
对中国经皮冠状动脉介入治疗患者进行了一项纵向研究。通过病历和问卷调查对预测变量进行了基线评估，问卷调查包括尼古丁依赖 Fagerström 测试、流行病学研究中心抑郁量表和吸烟自我效能问卷。通过电话或在心血管门诊常规就诊时，通过自我报告记录吸烟复发情况，时间分别为术后 3、6、9 和 12 个月。
共有 221 名在经皮冠状动脉介入治疗后立即戒烟的患者完成了整个研究。总体而言，12 个月内 51.1%（n=113）的患者吸烟复发。前 3 个月的患病率特别高（49.6%，n=56），随后几个月的患病率逐渐增加。有工作的患者、尼古丁依赖程度较高、抑郁症状较重、吸烟自我效能较低的患者更容易复发吸烟。
由于经皮冠状动脉介入治疗，在医院戒烟的患者中，吸烟复发的患病率较高。在经皮冠状动脉介入治疗后的患者中，吸烟复发的预测因素是就业、尼古丁依赖、抑郁和吸烟自我效能。
本研究可能促使医疗保健提供者关注吸烟复发问题，并为识别经皮冠状动脉介入治疗后复发风险较高的患者提供一些指导。
